REDWOOD CITY, Calif.,
March 31, 2021 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced the appointment of Marina
Bozilenko as an independent member of the company's Board of
Directors.
Ms. Bozilenko has over 30 years of investment banking and other
healthcare industry experience, including raising more than
$30 billion in capital and executing
numerous M&A transactions. She currently serves as a strategic
advisor to William Blair &
Company, a firm she joined in 2010 as head of biotech & pharma
and managing director. Prior to that, she worked at Bear, Stearns
& Co. Inc. as a senior managing director in the healthcare
group, at Bank of America Securities as a managing director and
head of biotechnology, and at Vector Securities International,
where she was a partner. Ms. Bozilenko was also a principal at Kidd
& Company, a private-equity firm. She received her B.A. in
molecular biology and M.A. in economic history from the
University of Chicago.
"Marina is a noted expert in driving and supporting the growth
of innovative companies within the healthcare, biotechnology and
pharmaceutical sectors and we are delighted with her addition to
our board," said Vince Angotti, Chief Executive Officer of
AcelRx. "We are thrilled with the timing of her arrival to the team
as we gain momentum in formulary approvals and market penetration.
We look forward to benefitting from Marina's extensive financial
and business development expertise in the biotech and life sciences
sectors."
"I'm excited to join AcelRx and contribute to its efforts to
offer patients and healthcare providers a unique alternative to
manage their patients' acute pain," said Marina Bozilenko. "I
believe that AcelRx is well-positioned to leverage its existing
commercial infrastructure and product portfolio to license or
acquire complementary products to support its growth, and I look
forward to contributing my corporate development and transactional
experience to these growth efforts."
About DSUVIA (sufentanil sublingual tablet), 30
mcg
DSUVIA®, known as DZUVEO™ in Europe, is indicated for use
in adults in certified medically supervised healthcare settings,
such as hospitals, surgical centers, and emergency departments, for
the management of acute pain severe enough to require an opioid
analgesic, and for which alternative treatments are inadequate.
DSUVIA was designed to provide rapid analgesia via a non-invasive
route and to eliminate dosing errors associated with intravenous
(IV) administration. DSUVIA is a single-strength solid dosage form
administered sublingually via a single-dose applicator (SDA) by
healthcare professionals. Sufentanil is an opioid analgesic
previously only marketed for IV and epidural anesthesia and
analgesia. The sufentanil pharmacokinetic profile
when delivered sublingually avoids the high peak plasma levels and
short duration of action observed with IV administration. The
European Commission approved DZUVEO for marketing
in Europe and the Company is currently in discussions
with potential European marketing partners. This release is
intended for investors only. For more information, including
important safety information and black box warning for DSUVIA,
please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised
settings. AcelRx's proprietary, non-invasive sublingual
formulation technology delivers sufentanil with consistent
pharmacokinetic profiles. AcelRx has one approved product in
the U.S., DSUVIA® (sufentanil sublingual
tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the
management of acute pain severe enough to require an opioid
analgesic for adult patients in certified medically supervised
healthcare settings, and one product candidate,
Zalviso® (sufentanil sublingual tablet system, SST
system, 15 mcg), an investigational product in the U.S., is
being developed as an innovatively designed patient-controlled
analgesia (PCA) system for reduction of moderate-to-severe acute
pain in medically supervised settings. DZUVEO and Zalviso are both
approved products in Europe. For additional information about
AcelRx, please visit www.acelrx.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to our
expectations for the benefits we may realize from Ms. Bozilenko's
appointment to our board of directors. These and any other
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by the use of forward-looking
terminology such as "believes," "expects," "anticipates," "may,"
"will," "should," "seeks," "approximately," "intends," "plans,"
"estimates," or the negative of these words or other comparable
terminology. The discussion of financial trends, strategy, plans or
intentions may also include forward-looking statements. These
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from those
projected, anticipated or implied by such statements, including the
risk that upcoming datasets are not published. Although it is not
possible to predict or identify all such risks and uncertainties,
they may include, but are not limited to, those described in
AcelRx's annual, quarterly and current reports (i.e., Form 10-K,
Form 10-Q and Form 8-K) as filed or furnished with
the Securities and Exchange Commission (SEC). You are
cautioned not to place undue reliance on any such forward-looking
statements, which speak only as of the date such statements were
first made. AcelRx's SEC reports are available
at www.acelrx.com under the "Investors" tab. Except to
the extent required by law, AcelRx undertakes no obligation to
publicly release the result of any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof, or to reflect the occurrence of unanticipated
events.
![AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.) AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)](https://mma.prnewswire.com/media/10977/acelrx_pharmaceuticals_inc_logo1838_21100jpg.jpg)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-appointment-of-marina-bozilenko-to-the-board-of-directors-301259388.html
SOURCE AcelRx Pharmaceuticals, Inc.